BioSpace News Archive

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced that Company management will present at two upcoming investor conferences.

Vapotherm, Inc., updated its fiscal year 2021 revenue expectations and announced it will expand its disposables production capacity.

Orchard Therapeutics, a global gene therapy leader, announced that the company will webcast a virtual R&D Investor Event on Tuesday, September 14, 2021, from 7:00 a.m. to 8:00 a.m. ET.

Immunocore announces that United Kingdom’s Medicines and Healthcare products Regulatory Agency has accepted a Market Authorisation Application seeking the approval of tebentafusp for the treatment of patients with metastatic uveal melanoma.

Recro Pharma, Inc. and BioCorRx, Inc. announced the expansion of the companies’ ongoing relationship with the signing of a new development and manufacturing agreement.

Galera Therapeutics, Inc. announced final results from its Phase 1/2 pilot trial of its dismutase mimetic, GC4419, versus placebo, in patients with unresectable or borderline resectable locally advanced pancreatic cancer, who are undergoing stereotactic body radiation therapy.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that the Company will participate in three investor conferences in September.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that its partner, Sumitomo Pharmaceuticals Co., Ltd. has received approval to market oral and intravenous formulations of XENLETA® for the treatment of community-acquired pneumonia in adults in Taiwan.

Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, announced a clinical research collaboration studying COVID-19 variants.

atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects, announced the appointment of Andrew Cleeland to the company’s Board of Directors.